# Understanding the Guardant360 Report

The report is easy to navigate with results located on three main pages - the Therapy Finder Page, Tumour Biology Page and Clinical Trial Page.

## Therapy Finder Page

This page contains a table summarizing the genetic alterations identified and their associated therapies. Therapies associated with genetic alterations that are FDA-approved within the indication of the patient are marked with a green symbol, those approved but in a different clinical setting are marked with a yellow symbol, and those associated with lack of response to a therapy are marked with a red symbol. If multiple alterations are identified, actionable alterations are included at the top. Variants of uncertain significance and synonymous alterations which are not currently actionable, are listed separately. Microsatellite instability is reported for all patients, the status can be found below the table and comments. A patient in which microsatellite instability is not detected will read “MSI-High NOT DETECTED”.

**Garcia, Ann** (A12345)
Patient MRN: MR123456 | DOB: NOV-01-1971 | Gender: Female
Diagnosis: Non-small cell lung cancer (NSCLC) | Test Number 1

GUARDANT360
Therapy Finder Page

| REPORTING | |
|---|---|
| Report Date: | DEC-05-2017 |
| Receipt Date: | NOV-24-2017 |
| Collection Date: | NOV-22-2017 |
| Specimen: | Blood |
| Status: | FINAL |

**PHYSICIAN**
**Michael Johnson**
Account: Pleasantville Oncology
Address: 1234 Main Street
Pleasantville, CA 91234, United States
Ph: (123) 456-7890 | Fax: (123) 456-7899
Additional Recipient: N/A

*Complete Tumor Response Map on page 2*



**Summary of Somatic Alterations & Associated Treatment Options**

KEY ✓ Approved in indication ~ Approved in other indication ✗ Lack of response

| Alteration | % cfDNA or Amplification | Associated FDA-approved therapies | Clinical trial availability (see page 3) |
|---|---|---|---|
| *CD74-ROS1* Fusion | 2.0% | ✓ Crizotinib<br>~ Cabozantinib | Yes |
| *NF1* S365* | 2.9% | ~ Cobimetinib, Everolimus, Temsirolimus, Trametinib | Yes |
| *TP53* Q331* | 1.8% | None | Yes |

Variants of Uncertain Significance
*AR* D891N (2.7%), *ARID1A* S334L (1.4%), *ROS1-CD74* Fusion (0.6%), *NF1* N1984S (0.4%)
The functional consequences and clinical significance of alterations are unknown. Relevance of therapies targeting these alterations is uncertain.

Synonymous Alterations
*EGFR* S921S (0.2%)
This sequence change does not alter the amino acid at this position and is unlikely to be a therapeutic target. Clinical correlation is advised.

**Comments**

In this patient, both a CD74-ROS1 fusion and a ROS1-CD74 fusion were detected in circulating cell-free DNA. The ROS1-CD74 fusion represents the reciprocal gene rearrangement of the CD74-ROS1 gene rearrangement and is detected in circulating cell-free DNA in this patient. The clinically significant rearrangement for this patient is the CD74-ROS1 fusion.

Microsatellite status: MSI-High NOT DETECTED

## Tumour Biology Page

This page includes the same alterations, but in the context of the Guardant360 Tumour Response Map. The mutations are listed in descending order of percent of cell free DNA. The Tumour Response Map helps understand the relative levels of cell free DNA of various alterations detected, as well as tracking changes in an alteration over time.

**Garcia, Ann** (A12345)
DOB: NOV-01-1971 | Test Number 1

GUARDANT360
Tumor Biology Page

### Guardant360 Tumor Response Map

The Guardant360 Tumor Response Map illustrates the variant allele fraction (% cfDNA) of observed somatic variants at each sample submission time point. Amplifications are not plotted, and only the first and last five test dates are plotted. Please see the Physician Portal (portal.guardanthealth.com) for the Tumor Response Map with all test dates.




| Alteration | % cfDNA or Amp | |
|---|---|---|
| *NF1* S365* | 2.9% | |
| *AR* D891N | 2.7% | Variant of Uncertain Significance § |
| *CD74-ROS1* Fusion | 2.0% | |
| *TP53* Q331* | 1.8% | |
| *ARID1A* S334L | 1.4% | Variant of Uncertain Significance § |
| *ROS1-CD74* Fusion | 0.6% | Variant of Uncertain Significance § |
| *NF1* N1984S | 0.4% | Variant of Uncertain Significance § |
| *EGFR* S921S | 0.2% | Synonymous Alteration § |

The table above annotates the variant allele fraction (% cfDNA) detected in this sample, listed in descending order.
§ See definitions section for more detail

## Clinical Trial Page

This page lists any clinical trials for the tumour type and mutations found that may be available in the ordering country.

**Garcia, Ann** (A12345)
DOB: NOV-01-1971 | Test Number 1

GUARDANT360
Clinical Trial Page

### Available Clinical Trials (within the same state as the ordering physician)

There may be additional trials not listed here. Visit: portal.guardanthealth.com or email clientservices@guardanthealth.com with A79934 in the subject line of the email, for additional trials.

| Alteration | Trial ID / Contact | Title | Phase | Site(s) |
|---|---|---|---|---|
| *CD74-ROS1* Fusion | NCT00585195<br>Pfizer CT.gov Call Center, ClinicalTrials.gov_Inquiries@pfizer.com, 1-800-718-1021 | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer | Phase 1 | Orange, California (2) |
| | NCT02465060 | NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma | Phase 2 | Anaheim, California<br>Antioch, California<br>Auburn, California (2)<br>Bakersfield, California<br>Additional trial sites available |
| | NCT02568267<br>For trial information and details on available travel support for eligible patients contact Ignyta Inc., STARTRKtrials@ignyta.com, 1-844-782-7875 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Phase 2 | Duarte, California<br>La Jolla, California (2)<br>Los Angeles, California<br>Orange, California<br>Additional trial sites available |
| | Visit portal.guardanthealth.com for trials not within the same state as the physician's office | | | |
| *NF1* S365* | NCT02890069<br>Novartis Pharmaceuticals, Novartis.email@novartis.com, 1-888-669-6682 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Phase 1 | Santa Monica, California |
| | NCT03087448<br>Collin Blakely, MD, PhD, collin.blakely@ucsf.edu, 415-885-3882 | Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Phase 1/ Phase 2 | San Francisco, California |
| | Visit portal.guardanthealth.com for trials not within the same state as the physician's office | | | |
| *TP53* Q331* | Visit portal.guardanthealth.com for trials not within the same state as the physician's office | | | |

More clinical trial options available at portal.guardanthealth.com



## Questions

If you have any question (about interpreting the report) please contact the Client Services at clientserviceseurope@guardanthealth.com